RetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal Diseases
RetinalGenix (OTCQB: RTGN) announced a research collaboration with Seer (Nasdaq: SEER) on Oct 16, 2025 to combine RetinalGenix’s ultra-high-resolution retinal imaging with Seer Bio’s proteomic profiling.
The agreement tasks Seer Bio with research, development, and clinical validation programs to identify molecular and cellular biomarkers for earlier detection and monitoring of systemic, neurodegenerative, and retinal diseases, naming Alzheimer’s, Parkinson’s, diabetic retinopathy, and cardiovascular disease as targets. The companies say the work aims to enable earlier, noninvasive detection and broader deployment of diagnostic solutions in clinical and home settings.
RetinalGenix (OTCQB: RTGN) ha annunciato una collaborazione di ricerca con Seer (Nasdaq: SEER) il 16 ottobre 2025 per combinare l’imaging della retina ad ultra‑alta risoluzione di RetinalGenix con la profilazione proteomica di Seer Bio.
L’accordo assegna a Seer Bio programmi di ricerca, sviluppo e validazione clinica finalizzati a identificare biomarcatori molecolari e cellulari per la rilevazione precoce e il monitoraggio di malattie sistemiche, neurodegenerative e retinali, citando Alzheimer, Parkinson, retinopatia diabetica e malattie cardiovascolari tra gli obiettivi. Le aziende affermano che l’obiettivo è permettere una rilevazione più precoce e non invasiva e una più ampia diffusione di soluzioni diagnostiche in contesti clinici e domiciliari.
RetinalGenix (OTCQB: RTGN) anunció una colaboración de investigación con Seer (Nasdaq: SEER) el 16 de octubre de 2025 para combinar la imagen de retina de ultra alta resolución de RetinalGenix con el perfil proteómico de Seer Bio.
El acuerdo encomienda a Seer Bio programas de investigación, desarrollo y validación clínica para identificar biomarcadores moleculares y celulares para la detección temprana y el seguimiento de enfermedades sistémicas, neurodegenerativas y retinales, citando como objetivos el Alzheimer, la enfermedad de Parkinson, la retinopatía diabética y las enfermedades cardiovasculares. Las compañías afirman que el trabajo busca permitir una detección más temprana y no invasiva y una mayor difusión de soluciones diagnósticas en entornos clínicos y en el hogar.
RetinalGenix (OTCQB: RTGN)는 2025년 10월 16일 Seer (나스닥: SEER)와 연구 협력을 발표하여 RetinalGenix의 초고해상도 망막 영상과 Seer Bio의 단백질 프로파일링을 결합합니다.
해당 계약은 Seer Bio에 연구, 개발 및 임상 검증 프로그램을 지시하여 신경계 및 망막 질환뿐 아니라 전신 질환의 조기 발견 및 모니터링을 위한 분자 및 세포 생물학적 바이오마커를 식별하도록 하며, 알츠하이머병, 파킨슨병, 당뇨병성 망막병증 및 심혈관 질환을 목표로 명시합니다. 양사는 이 연구가 조기 비침습적 진단과 임상 및 가정 환경에서의 진단 솔루션의 광범위한 적용을 가능하게 하는 것을 목표로 한다고 말합니다.
RetinalGenix (OTCQB: RTGN) a annoncé le 16 octobre 2025 une collaboration en recherche avec Seer (Nasdaq: SEER) pour combiner l’imagerie rétinienne ultra-haute résolution de RetinalGenix avec le profil protéomique de Seer Bio.
L’accord charge Seer Bio de programmes de recherche, développement et validation clinique afin d’identifier des biomarqueurs moléculaires et cellulaires pour la détection précoce et le suivi des maladies systémiques, neurodégénératives et rétiniennes, en citant l’Alzheimer, la maladie de Parkinson, la rétinopathie diabétique et les maladies cardiovasculaires comme cibles. Les entreprises indiquent que ce travail vise à permettre une détection plus précoce et non invasive et un déploiement plus large de solutions diagnostics en milieux cliniques et à domicile.
RetinalGenix (OTCQB: RTGN) kündigte am 16. Oktober 2025 eine Forschungskooperation mit Seer (Nasdaq: SEER) an, um die ultrascharfe Netzhautbildgebung von RetinalGenix mit dem Proteomprofiling von Seer Bio zu kombinieren.
Der Vertrag beauftragt Seer Bio mit Forschungs-, Entwicklungs- und klinischen Validierungsprogrammen, um molekulare und zelluläre Biomarker für die frühere Erkennung und Überwachung von systemischen, neurodegenerativen und retinalen Erkrankungen zu identifizieren, wobei Alzheimer, Parkinson, diabetische Retinopathie und Herz-Kreislauf-Erkrankungen als Ziele genannt werden. Die Unternehmen sagen, dass die Arbeit darauf abzielt, eine frühere, nicht-invasive Erkennung zu ermöglichen und die Bereitstellung von diagnostischen Lösungen in klinischen und häuslichen Umgebungen breiter zu unterstützen.
RetinalGenix (OTCQB: RTGN) أعلنت عن تعاون بحثي مع Seer (ناسداك: SEER) في 16 أكتوبر 2025 لدمج التصوير الشبكي عالي الدقة للشبكية من RetinalGenix مع تحليل بروتيومي لبروتين Seer Bio.
توكّل الاتفاقية Seer Bio ببرامج البحث والتطوير والتحقق الإكلينيكي لتحديد عوامل بيومركرز جزيئية وخلوية للكشف المبكر ومراقبة أمراض جهازية ومرض neurodegenerative و retinal، مع ذكر الزهايمر، مرض باركنسون، اعتلال الشبكية السكري وأمراض القلب والأوعية الدموية كأهداف. تقول الشركات أن العمل يهدف إلى تمكين الكشف المبكر وغير الجراحي والتوسع في نشر حلول التشخيص في البيئات السريرية والمنزلية.
RetinalGenix (OTCQB: RTGN) 公布与 Seer (纳斯达克：SEER) 于 2025 年 10 月 16 日的研究合作，将 RetinalGenix 的超高分辨率视网膜成像与 Seer Bio 的蛋白质组分析相结合。
协议要求 Seer Bio 开展研究、开发和临床验证计划，以识别分子和细胞生物标志物，用于更早发现和监测全身性、神经退行性和视网膜疾病，目标包括阿尔茨海默病、帕金森病、糖尿病性视网膜病变和心血管疾病。双方表示，这项工作旨在实现更早的、非侵入性检测，并在临床和家庭环境中更广泛地部署诊断解决方案。
- None.
- None.
APOLLO BEACH, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. [OTCQB: RTGN] (“RetinalGenix” or the “Company”), a company developing ultra-high-resolution retinal imaging technology, today announced it has engaged Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, to help identify novel biomarkers that enable earlier detection and more precise monitoring of systemic, neurodegenerative, and retinal diseases.
By integrating RetinalGenix’s non-invasive retinal imaging platform with Seer Bio’s advanced proteomic profiling, RetinalGenix aims to uncover molecular and cellular signatures associated with disease onset, progression, and risk—often before clinical symptoms appear. The collaboration targets a range of critical conditions, including Alzheimer’s disease, Parkinson’s disease, diabetic retinopathy, and cardiovascular diseases.
Under the agreement, RetinalGenix has contracted Seer Bio to conduct research, development, and clinical validation programs designed to accelerate diagnostic innovation. The approach is intended to enable broader deployment of early-detection solutions in both clinical and home-based care settings, strengthening the potential for improved patient outcomes and reduced healthcare costs.
“Our relationship is focused on integrating ultra-high-resolution retinal imaging with advanced molecular biomarker analysis to rapidly identify and characterize disease signatures of the eye and body,” said Jerry Katzman, MD, Chairman, President, and CEO of RetinalGenix Technologies Inc. and its subsidiary DNA/RNA GPS. “The goal is to establish comprehensive biomarker profiles that not only support earlier detection and better disease monitoring, but also create pathways toward predictive modeling for degenerative and metabolic conditions.”
The collaboration underscores the shared vision of both companies: to transform early disease detection and usher in a new era of personalized precision medicine and diagnostic care through the convergence of imaging and proteomics.
About Seer Bio
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with a scale, speed, precision, and reproducibility previously unattainable. Seer’s Proteograph® Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges that conventional methods have failed to overcome. Traditional proteomic technologies have historically struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer’s robust and scalable workflow consistently reveals biological insights that others do not. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information about Seer’s differentiated approach and ongoing leadership in proteomics, visit www.seer.bio.
About RetinalGenix Technologies Inc.
RetinalGenix is an ophthalmic research and development company seeking to revolutionize early disease detection and improve patient outcomes across multiple disease areas by integrating genetic screening, advanced imaging, and therapeutic development. Its proprietary High-Resolution Retinal Imaging and RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular, and metabolic systems, as well as diabetic conditions, Alzheimer’s disease, Complex Dementia, and Parkinson’s disease. RetinalGenix is also developing therapeutic drugs for dry age-related macular degeneration (dry AMD) and Alzheimer’s disease/dementia.
Safe Harbor Statement
This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements and include statements regarding identifying novel biomarkers that enable earlier detection and more precise monitoring of neurodegenerative, systemic, and retinal diseases, integrating RetinalGenix’s non-invasive retinal imaging platform with Seer Bio’s advanced proteomic profiling, uncovering molecular and cellular signatures associated with disease onset, progression, and risk—often before clinical symptoms appear, the collaboration targeting a range of critical conditions, including Alzheimer’s disease, Parkinson’s disease, diabetic retinopathy, and cardiovascular diseases, jointly conducting research, development, and clinical validation programs designed to accelerate diagnostic innovation, the combined approach enabling broader deployment of early-detection solutions in both clinical and home-based care settings, strengthening the potential for improved patient outcomes and reduced healthcare costs, integrating ultra high resolution retinal imaging with advanced molecular biomarker analysis to rapidly identify and characterize disease signatures of the eye and body, establishing comprehensive biomarker profiles that not only support earlier detection and better disease monitoring, but also create pathways toward predictive modeling for degenerative and metabolic conditions and transforming early disease detection and ushering in a new era of personalized diagnostic care through the convergence of imaging and proteomics. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability use its and Seer’s technologies to identify novel biomarkers that enable earlier detection and more precise monitoring of neurodegenerative, systemic, and retinal diseases, the Company’s ability to integrate its retinal imaging platform with Seer Bio’s advanced proteomic profiling technology, the Company’s ability to successfully complete research and further development and commercialization of the Company’s products, the timing, cost and uncertainty of obtaining regulatory approvals for the Company’s products, the Company’s ability to protect its intellectual property, and the risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Media Contacts:
RetinalGenix Technologies Inc.
Media and Investor Relations
ir@retinalgenix.com
(800) 331-5446
Seer Bio
pr@seer.bio
FAQ
What did RetinalGenix (RTGN) announce on October 16, 2025 regarding Seer?
Which diseases will the RTGN and Seer collaboration target?
What is the goal of combining RetinalGenix imaging with Seer Bio proteomics for RTGN investors?
Will the RTGN–Seer work include clinical validation and when did the agreement occur?
How might the RTGN and Seer partnership affect deployment of diagnostics?
Does the announcement state any revenue, funding size, or regulatory approvals for RTGN (RTGN)?
